Xeris Pharmaceuticals (XERS) Stock Statistics & Valuation Metrics

Xeris Pharmaceuticals has a market cap or net worth of $941.47M. The enterprise value is $873.37M.

Xeris Pharmaceuticals has 172,431,290 shares outstanding. The number of shares has decreased by -2.65% in one year.

Xeris Pharmaceuticals’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 8.89%.

The current PE Ratio of Xeris Pharmaceuticals is 2273.2. Xeris Pharmaceuticals’s PEG ratio is -22.52.

In the last 12 months, Xeris Pharmaceuticals had revenue of 291.85M and earned 554.00K in profits. Earnings per share was <0.01.

In the last 12 months, operating cash flow was 28.63M and capital expenditures -696.00K, giving a free cash flow of 37.78M billion.

Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Xeris Pharmaceuticals upcoming earnings date is May 7, 2026, Before Open (Confirmed).

Xeris Pharmaceuticals as a current ratio of 2.19, with Debt / Equity ratio of 275.86%

In the past 12 months, Xeris Pharmaceuticals has paid 0.00 in taxes.

Xeris Pharmaceuticals EV to EBITDA ratio is 93.32, with an EV/FCF ratio of 42.47.

Xeris Pharmaceuticals has $111.04M in cash and marketable securities with $37.76M in debt, giving a net cash position of $73.28M billion.

Gross margin is 81.70%, with operating margin of 8.53%, and net profit margin of 0.19%.

The average price target for Xeris Pharmaceuticals is $10.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy